Logo

SNOA

Sonoma Pharmaceuticals, Inc.

SNOA

Sonoma Pharmaceuticals, Inc. • NASDAQ
$3.39 ▲ 4.63% (+0.15)
Market Cap $5.77 M
52w High $6.92
52w Low $1.75
Dividend Yield 0%
P/E -1.69
Volume 213
Outstanding Shares 1.70M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2026 $5.604M ▲ $2.457M ▼ $-534K ▲ -9.529% ▲ $-0.32 ▲ $-695K ▲
Q1-2026 $4.015M ▲ $2.559M ▲ $-1.241M ▼ -30.909% ▼ $-0.76 ▼ $-1.059M ▼
Q4-2025 $3.754M ▲ $2.184M ▼ $-776K ▲ -20.671% ▲ $-0.63 $-625K ▲
Q3-2025 $3.564M ▼ $2.301M ▲ $-928K ▼ -26.038% ▼ $-0.63 ▼ $-998K ▼
Q2-2025 $3.579M $2.211M $-610K -17.044% $-0.59 $-815K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2026 $3.035M ▼ $13.856M ▼ $10.069M ▼ $3.787M ▼
Q1-2026 $3.605M ▼ $14.594M ▲ $10.538M ▲ $4.056M ▼
Q4-2025 $5.374M ▲ $13.693M ▲ $9.282M ▲ $4.411M ▼
Q3-2025 $5.236M ▲ $13.668M ▼ $8.798M ▲ $4.87M ▼
Q2-2025 $4.078M $13.685M $8.333M $5.352M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2026 $-776K ▲ $-95K ▲ $-47K ▲ $242K ▲ $138K ▲ $-142K ▲
Q1-2026 $-1.241M ▼ $-2.015M ▼ $-106K ▼ $-58K ▼ $-1.769M ▼ $-2.121M ▼
Q4-2025 $-928K ▼ $565K ▲ $-2K ▲ $708K ▼ $1.158M ▼ $563K ▲
Q3-2025 $-610K $354K $-26K $1.444M $1.489M $328K
Q2-2025 $-610K $354K $-26K $1.444M $1.489M $328K

Revenue by Products

Product Q3-2025Q4-2025Q1-2026Q2-2026
Animal Care
Animal Care
 $0 ▲$0 ▲$0 ▲$0 ▲
Human Care
Human Care
 $0 ▲$10.00M ▲$0 ▼$10.00M ▲
Product
Product
 $0 ▲$0 ▲$0 ▲$0 ▲
Service And Royalty
Service And Royalty
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Sonoma’s income statement shows a very small revenue base and a long history of operating losses. Gross profit exists but is thin, and operating results hover around break-even to modestly negative, with net losses recurring year after year. Earnings per share look heavily negative, though this is also affected by repeated reverse stock splits over time. Overall, the business has not yet reached consistent scale or profitability, and the income statement reflects an early-stage or niche company still struggling to convert its technology into durable earnings.

Balance Sheet

Balance Sheet The balance sheet is small and fairly simple. Total assets are modest, with cash being a meaningful portion of what the company owns. There is effectively no traditional interest-bearing debt, which reduces financial strain but also signals that growth has not been funded by large borrowings. Shareholder equity is positive but limited, and repeated reverse splits highlight a history of capital restructuring to remain listed. In short, the company is lightly leveraged but also lightly capitalized, leaving only a modest cushion to absorb setbacks.

Cash Flow

Cash Flow Cash flows appear fragile but not catastrophic. Operating cash flow has mostly hovered around breakeven, with at least one period of noticeable cash burn. Capital spending needs are very low, so free cash flow tracks closely with operating cash flow. The main risk is that, with a small revenue base and limited assets, any uptick in losses or working-capital needs could quickly pressure cash. Sustainability of operations likely depends on careful cost control and ongoing access to external funding rather than internally generated cash.

Competitive Edge

Competitive Edge Sonoma occupies a narrow but distinct niche in healthcare, built around its Microcyn hypochlorous acid platform. Its edge comes from patented formulations, specialized manufacturing know-how, and a library of regulatory clearances and clinical data. This gives the company credibility in wound care, dermatology, eye care, and animal health, and raises the bar for direct copycats. However, it competes in markets dominated by much larger pharmaceutical and consumer-health companies with stronger brands, bigger sales forces, and deeper marketing budgets. The moat is more technological and regulatory than commercial; the main challenge is turning this niche expertise into broad, lasting market share.

Innovation and R&D

Innovation and R&D Innovation is the clear strength. Microcyn technology offers a stable, gentle, broad-acting antimicrobial platform that can be used in many forms: liquids, gels, and combination products like scar treatments. Sonoma has in-house manufacturing, a base of clinical studies, and a growing list of regulatory clearances, including recent U.S. approvals and cosmetic registrations. The company is pushing into new areas such as consumer skincare, baby care, and office-dispensed dermatology products, often via retail and distribution partnerships. The key uncertainty is not whether the technology works—it appears well-validated—but whether Sonoma can innovate commercially at the same pace, building strong brands and sales channels that finally match its scientific potential.

Summary

Sonoma Pharmaceuticals is a small, innovation-driven healthcare company with a technically strong but commercially under-scaled business. Its income statement and cash flows show a persistent struggle to achieve meaningful profitability, with a tiny revenue base and recurring losses. The balance sheet is clean of debt but thin, leaving limited room for prolonged missteps without raising more capital. On the positive side, Sonoma has a differentiated technology, solid intellectual property, and regulatory and clinical backing that give it a real niche in hypochlorous acid–based therapies. The company is now leaning into consumer, cosmetic, and dermatology channels through large retail and distribution partners, which could broaden its reach. The overarching question is execution: can Sonoma transform its scientific and regulatory strengths into durable commercial traction and scale before its financial flexibility narrows further.

NEWS

November 13, 2025 · 8:30 AM UTC

National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced

Read more

November 6, 2025 · 4:01 PM UTC

Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Düsseldorf

Read more

November 4, 2025 · 8:56 AM UTC

Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2026 Financial Results

Read more

October 14, 2025 · 8:30 AM UTC

Sonoma Pharmaceuticals and Medline Industries Launch New HOCl Wound Cleanser for U.S. Hospitals

Read more

October 7, 2025 · 8:30 AM UTC

Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA

Read more